Recommended Systemic Therapy for Sarcoidosis
For symptomatic pulmonary sarcoidosis at risk of mortality or permanent disability, initiate glucocorticoids (prednisone 20-40 mg daily) as first-line therapy, add methotrexate as second-line for steroid-sparing or refractory disease, and escalate to infliximab for advanced disease unresponsive to prior treatments. 1, 2
Treatment Algorithm by Disease Phenotype
First-Line: Glucocorticoids
- Start prednisone 20-40 mg daily for symptomatic disease or organ-threatening involvement 2
- Allow 3-6 months to assess therapeutic response before escalating therapy 2
- Glucocorticoids improve and preserve FVC and quality of life in patients at higher risk of future mortality or permanent disability 1
Important caveat: Nearly half of sarcoidosis patients never require systemic treatment 2. Asymptomatic pulmonary disease does not benefit from corticosteroid treatment in altering natural history 2.
Second-Line: Add Methotrexate
Indications for adding methotrexate 1, 2:
- Continued disease despite glucocorticoids
- Unacceptable glucocorticoid side-effects
- High risk for steroid toxicity
- Expectation of prolonged/high-dose steroid therapy
- Inability to wean prednisone to ≤10 mg daily
Recent breakthrough evidence: A 2025 randomized controlled trial demonstrated that methotrexate is noninferior to prednisone as first-line therapy for pulmonary sarcoidosis, with adjusted between-group difference of -1.17 percentage points in FVC (95% CI: -4.27 to 1.93) 3. This challenges traditional treatment paradigms and supports earlier methotrexate use in selected patients.
- Methotrexate is the preferred second-line agent based on multiple clinical trials including placebo-controlled data 2
- Oral administration is favored; consider subcutaneous for GI side-effects 2
- Alternative second-line agents (azathioprine, mycophenolate, leflunomide) did not reach consensus 2
Steroid tapering strategy: Once disease stabilizes or improves, decrease prednisone to the lowest dose providing satisfactory symptom relief and disease control 2
Third-Line: Biologics (Infliximab)
Indications for escalating to biologics 1, 2:
- Severe or progressive disease
- Inadequate response to glucocorticoids plus immunosuppressants
- Toxicity from prior therapies
- Advanced disease phenotype
Infliximab is the preferred biologic agent with multiple clinical trials supporting efficacy across various sarcoidosis manifestations 2. Continue biologics for 2-3 years with corticosteroids tapered to lowest effective dose 2.
- Adalimumab has shown effectiveness in some patients but is considered an alternative 2
- Other anti-TNF agents (golimumab, etanercept) were NOT effective in most patients 2
- Rituximab has limited data and did not reach consensus 2
Special Considerations
Cutaneous Sarcoidosis
- Glucocorticoids recommended for cosmetically important involvement 1
- Hydroxychloroquine specifically considered for skin disease or hypercalcemia 2
Cardiac and Neurologic Sarcoidosis
- Recent evidence supports anti-TNF agents for refractory cardiac sarcoidosis and neurosarcoidosis 4
- These organ-threatening manifestations warrant aggressive early treatment
Treatment Duration and Relapse Risk
Critical pitfall: Relapse rates are substantial upon therapy withdrawal:
- 20-80% relapse after 2 years of glucocorticoid therapy 1
- 80% require re-institution of therapy after methotrexate withdrawal 1
50% relapse after discontinuing infliximab at 6-12 months 1
Re-evaluate treatment need every 1-2 years to balance efficacy against toxicity 1
Prophylaxis and Monitoring
- Pneumocystis prophylaxis for high-dose immunosuppression (≥20 mg prednisone with cytotoxic agent for >6 months) 2
- Tuberculosis screening with interferon-γ testing before biologics 2
- Pneumococcal and influenza vaccination strongly recommended 2
Quality of Life Considerations
Prolonged low-dose prednisone causes significant toxicity including weight gain, insomnia, increased appetite, steroid-induced complications, and reduced quality of life 2. The 2025 trial showed methotrexate's side-effect profile (nausea, fatigue, abnormal liver function) may be preferable for some patients, informing shared decision-making 3.
The modern approach emphasizes early steroid-sparing strategies rather than prolonged prednisone monotherapy, which inadequately addresses disease progression and cumulative harm 2.